NEW YORK, May 1, 2009 (GLOBE NEWSWIRE) -- Roy Jacobs & Associates announces that it is investigating possible claims for the violation of the federal securities laws on behalf of purchasers of the common stock of Sequenom Inc. ("Sequenom" or the "Company") (Nasdaq:SQNM) during the period from June 4, 2008, through April 29, 2009, due to the failure by the Company and its management to disclose material negative information concerning the mishandling of test trials of the Company's key new prenatal Down syndrome test product. Now, it appears that none of the research and development data can be relied upon and these failures will cause the Down syndrome test to be significantly delayed.
For further information, please contact Roy L. Jacobs, Esq. toll-free at 1-888-884-4490 or by e-mail to rjacobs@jacobsclasslaw.com.
On April 29, 2009, after the market closed, Sequenom announced that the expected launch of its SEQureDx(tm) Down syndrome test will be delayed because of employee mishandling of SEQureDx test data and results. As a result, Sequenom stock has lost more than 75% of its trading value, falling from $14.91 to $3.62. The Company stated that "the company is no longer relying on the previously announced R&D test data and results" and that any commercial launch of SEQureDx(tm) will be delayed for an unknown period of time. The Company's announcement states that multiple prior press releases and public statements concerning SEQureDx(tm) can no longer be relied upon.
If you purchased Sequenom stock during the period from June 4, 2008, through April 29, 2009, and you have a loss on your shares (whether or not you have sold them), and are interested in discussing your rights free of charge, please contact Roy L. Jacobs. Mr. Jacobs will be glad to personally speak with you.